Mupadolimab is a humanized anti-CD73 monoclonal antibody that inhibits production of immunosuppressive adenosine in the tumour microenvironment, binding to CD73 on B cells leads to their activation (including increased antibody production). Mupadolimab was developed for the treatment of head and neck cancer, and NSCLC.